ChemoCentryx, Inc. (CCXI) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of ChemoCentryx, Inc. (NASDAQ:CCXI) from a buy rating to a hold rating in a research note released on Monday morning.
According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “
A number of other research firms also recently issued reports on CCXI. ValuEngine downgraded shares of ChemoCentryx from a hold rating to a sell rating in a research report on Friday, November 10th. BidaskClub cut shares of ChemoCentryx from a strong-buy rating to a buy rating in a report on Thursday, August 10th. Finally, Cowen and Company reaffirmed a hold rating on shares of ChemoCentryx in a report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $8.25.
ChemoCentryx (NASDAQ:CCXI) traded up $0.09 during trading on Monday, hitting $7.35. 49,400 shares of the stock were exchanged, compared to its average volume of 139,542. ChemoCentryx has a one year low of $6.13 and a one year high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.13. research analysts anticipate that ChemoCentryx will post -0.67 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “ChemoCentryx, Inc. (CCXI) Downgraded by Zacks Investment Research” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/chemocentryx-inc-ccxi-downgraded-by-zacks-investment-research/1709619.html.
Several hedge funds have recently added to or reduced their stakes in CCXI. Wasatch Advisors Inc. increased its holdings in shares of ChemoCentryx by 10.3% in the 2nd quarter. Wasatch Advisors Inc. now owns 2,255,438 shares of the biopharmaceutical company’s stock worth $21,111,000 after acquiring an additional 210,039 shares during the period. Renaissance Technologies LLC increased its holdings in shares of ChemoCentryx by 31.0% in the 1st quarter. Renaissance Technologies LLC now owns 616,581 shares of the biopharmaceutical company’s stock worth $4,489,000 after acquiring an additional 146,000 shares during the period. BB&T Securities LLC acquired a new stake in shares of ChemoCentryx in the 2nd quarter worth about $781,000. OxFORD Asset Management LLP increased its holdings in shares of ChemoCentryx by 37.3% in the 3rd quarter. OxFORD Asset Management LLP now owns 246,369 shares of the biopharmaceutical company’s stock worth $1,853,000 after acquiring an additional 66,910 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of ChemoCentryx in the 3rd quarter worth about $414,000. 49.15% of the stock is currently owned by institutional investors and hedge funds.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.